By Colin Kellaher

 

Insulet Corp. on Friday said it received U.S. Food and Drug Administration approval for its Omnipod 5 automated insulin-delivery system for individuals ages 6 and older with type 1 diabetes.

The Acton, Mass., medical-device company said the Omnipod 5 is the first tubeless automated delivery system that integrates with DexCom Inc.'s G6 continuous glucose monitoring system and a compatible smartphone to automatically adjust insulin and help protect against highs and lows.

Insulet said that it will launch Omnipod 5 through the pharmacy channel, and that it expects the device will be broadly available shortly after a limited market release.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

January 28, 2022 06:39 ET (11:39 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Insulet Charts.
Insulet (NASDAQ:PODD)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Insulet Charts.